Counterpoint Mutual Funds LLC Invests $556,000 in Azenta, Inc. $AZTA

Counterpoint Mutual Funds LLC acquired a new position in Azenta, Inc. (NASDAQ:AZTA) in the first quarter, Holdings Channel.com reports. The institutional investor acquired 26,306 shares of the company’s stock, valued at approximately $556,000.

Several other large investors have also recently added to or reduced their stakes in AZTA. Caitong International Asset Management Co. Ltd raised its stake in Azenta by 2,067.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock valued at $27,000 after acquiring an additional 765 shares in the last quarter. Assetmark Inc. grew its stake in shares of Azenta by 54.1% in the fourth quarter. Assetmark Inc. now owns 832 shares of the company’s stock worth $28,000 after purchasing an additional 292 shares in the last quarter. Osaic Holdings Inc. grew its stake in shares of Azenta by 44.9% in the second quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after purchasing an additional 385 shares in the last quarter. Rockefeller Capital Management L.P. increased its holdings in shares of Azenta by 98.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock valued at $46,000 after purchasing an additional 689 shares during the period. Finally, Van ECK Associates Corp increased its holdings in shares of Azenta by 141.2% during the fourth quarter. Van ECK Associates Corp now owns 1,585 shares of the company’s stock valued at $53,000 after purchasing an additional 928 shares during the period. 99.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on AZTA. Needham & Company LLC cut their price objective on shares of Azenta from $44.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Weiss Ratings lowered shares of Azenta from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $39.50.

Azenta Price Performance

AZTA opened at $25.84 on Friday. The business has a 50 day moving average price of $22.11 and a two-hundred day moving average price of $26.97. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -6.53 and a beta of 1.37. Azenta, Inc. has a 1-year low of $15.93 and a 1-year high of $41.73.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.16). Azenta had a negative net margin of 30.49% and a positive return on equity of 1.23%. The firm had revenue of $144.79 million for the quarter, compared to analyst estimates of $148.47 million. During the same quarter last year, the business posted $0.01 earnings per share. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year.

Azenta Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.